Hikaru Sugimoto

26.2k total citations · 14 hit papers
115 papers, 18.4k citations indexed

About

Hikaru Sugimoto is a scholar working on Molecular Biology, Nephrology and Cancer Research. According to data from OpenAlex, Hikaru Sugimoto has authored 115 papers receiving a total of 18.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 31 papers in Nephrology and 22 papers in Cancer Research. Recurrent topics in Hikaru Sugimoto's work include Cell Adhesion Molecules Research (21 papers), Chronic Kidney Disease and Diabetes (20 papers) and Renal Diseases and Glomerulopathies (18 papers). Hikaru Sugimoto is often cited by papers focused on Cell Adhesion Molecules Research (21 papers), Chronic Kidney Disease and Diabetes (20 papers) and Renal Diseases and Glomerulopathies (18 papers). Hikaru Sugimoto collaborates with scholars based in United States, Japan and Germany. Hikaru Sugimoto's co-authors include Raghu Kalluri, Valerie S. LeBleu, Michael Zeisberg, Sujuan Yang, Sónia A. Melo, Chia-Chin Wu, Sushrut Kamerkar, Joyce T. O’Connell, Julienne L. Carstens and J. Jack Lee and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Hikaru Sugimoto

111 papers receiving 18.2k citations

Hit Papers

Exosomes facilitate therapeuti... 2003 2026 2010 2018 2017 2015 2014 2003 2013 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
    2017 2.0k citations Valerie S. LeBleu, Hikaru Sugimoto et al. Nature profile →
  2. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
    2015 1.6k citations Xiaofeng Zheng, Julienne L. Carstens et al. Nature profile →
  3. Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis
    2014 1.3k citations Hikaru Sugimoto, Joyce T. O’Connell et al. Cancer Cell profile →
  4. BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury
    2003 1.1k citations Michael Zeisberg, Hikaru Sugimoto et al. Nature Medicine profile →
  5. Origin and function of myofibroblasts in kidney fibrosis
    2013 1.0k citations Valerie S. LeBleu, Gangadhar Taduri et al. Nature Medicine profile →
  6. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
    2015 749 citations Sara Lovisa, Valerie S. LeBleu et al. Nature Medicine profile →
  7. Fibroblasts in Kidney Fibrosis Emerge via Endothelial-to-Mesenchymal Transition
    2008 713 citations Elisabeth M. Zeisberg, Hikaru Sugimoto et al. profile →
  8. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function
    2005 647 citations Jochen Reiser, Christian Faul et al. profile →
  9. Generation and testing of clinical-grade exosomes for pancreatic cancer
    2018 633 citations Hikaru Sugimoto, Kathleen M. McAndrews et al. profile →
  10. Identification of fibroblast heterogeneity in the tumor microenvironment
    2006 572 citations Hikaru Sugimoto, Mark W. Kieran et al. profile →
  11. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer
    2021 373 citations Yang Chen, Jiha Kim et al. Cancer Cell profile →
  12. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer
    2022 191 citations Kathleen M. McAndrews, Yang Chen et al. Cancer Discovery profile →
  13. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer
    2022 164 citations Yang Chen, Sujuan Yang et al. Cancer Cell profile →
  14. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer.
    2022 136 citations Kathleen M. McAndrews, Yang Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hikaru Sugimoto United States 50 10.3k 4.9k 3.9k 3.5k 2.5k 115 18.4k
Michael Zeisberg Germany 55 10.6k 1.0× 3.6k 0.7× 5.6k 1.4× 3.6k 1.0× 2.1k 0.9× 105 21.1k
Peter J. Nelson Germany 67 4.8k 0.5× 1.7k 0.3× 3.9k 1.0× 2.0k 0.6× 4.6k 1.8× 252 13.8k
David L. Lacey United States 55 16.0k 1.6× 3.1k 0.6× 11.3k 2.9× 1.2k 0.4× 3.0k 1.2× 101 23.8k
Dontscho Kerjaschki Austria 79 8.4k 0.8× 1.2k 0.2× 6.7k 1.7× 6.5k 1.9× 3.6k 1.4× 225 21.3k
Elena Aïkawa United States 78 6.5k 0.6× 2.4k 0.5× 1.6k 0.4× 1.2k 0.4× 5.2k 2.0× 261 22.1k
Benedetta Bussolati Italy 53 7.7k 0.7× 3.2k 0.7× 1.6k 0.4× 1.0k 0.3× 1.3k 0.5× 202 11.7k
Ying E. Zhang United States 51 12.5k 1.2× 2.4k 0.5× 3.5k 0.9× 480 0.1× 1.3k 0.5× 102 16.4k
Keith A. Hruska United States 68 7.1k 0.7× 1.1k 0.2× 2.6k 0.7× 5.3k 1.5× 643 0.3× 269 15.2k
Hans‐Peter Gerber United States 51 12.1k 1.2× 4.6k 0.9× 5.7k 1.5× 330 0.1× 2.2k 0.9× 91 21.1k
Lucia R. Languino United States 58 6.3k 0.6× 2.5k 0.5× 2.0k 0.5× 760 0.2× 1.4k 0.6× 149 11.2k

Countries citing papers authored by Hikaru Sugimoto

Since Specialization
Citations

This map shows the geographic impact of Hikaru Sugimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hikaru Sugimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hikaru Sugimoto more than expected).

Fields of papers citing papers by Hikaru Sugimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hikaru Sugimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hikaru Sugimoto. The network helps show where Hikaru Sugimoto may publish in the future.

Co-authorship network of co-authors of Hikaru Sugimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Hikaru Sugimoto. A scholar is included among the top collaborators of Hikaru Sugimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hikaru Sugimoto. Hikaru Sugimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Xin, Fernanda G. Kugeratski, Dara P. Dowlatshahi, et al.. (2025). Engineered Immunomodulatory Extracellular Vesicles from Epithelial Cells with the Capacity for Stimulation of Innate and Adaptive Immunity in Cancer and Autoimmunity. ACS Nano. 19(5). 5193–5216. 3 indexed citations
2.
Sugimoto, Hikaru, Wenhua Guo, Vivek Boominathan, et al.. (2024). Single Extracellular Vesicle Imaging and Computational Analysis Identifies Inherent Architectural Heterogeneity. ACS Nano. 18(18). 11717–11731. 16 indexed citations
3.
Mahadevan, Krishnan K., Yang Chen, Bingrui Li, et al.. (2024). Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 384(6703). eadh4567–eadh4567. 20 indexed citations
4.
Haltom, Amanda R., Janine Hensel, Jiha Kim, et al.. (2022). Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. SHILAP Revista de lepidopterología. 1. 100014–100014. 23 indexed citations
5.
McAndrews, Kathleen M., Yang Chen, J. Kebbeh Darpolor, et al.. (2022). Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Cancer Discovery. 12(6). 1580–1597. 191 indexed citations breakdown →
6.
McAndrews, Kathleen M., Toru Miyake, Ehsan A. Ehsanipour, et al.. (2022). Dermal αSMA + myofibroblasts orchestrate skin wound repair via β1 integrin and independent of type I collagen production. The EMBO Journal. 41(7). e109470–e109470. 54 indexed citations
7.
Chen, Yang, Sujuan Yang, Sara Lovisa, et al.. (2021). Type-I collagen produced by distinct fibroblast lineages reveals specific function during embryogenesis and Osteogenesis Imperfecta. Nature Communications. 12(1). 7199–7199. 85 indexed citations
8.
Chen, Yang, Jiha Kim, Sujuan Yang, et al.. (2021). Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 39(4). 548–565.e6. 373 indexed citations breakdown →
9.
Lovisa, Sara, Eliot Fletcher-Sananikone, Hikaru Sugimoto, et al.. (2020). Endothelial-to-mesenchymal transition compromises vascular integrity to induce Myc-mediated metabolic reprogramming in kidney fibrosis. Science Signaling. 13(635). 95 indexed citations
10.
Eikesdal, Hans Petter, Lisa M. Becker, Yingqi Teng, et al.. (2018). BMP7 Signaling in TGFBR2 -Deficient Stromal Cells Provokes Epithelial Carcinogenesis. Molecular Cancer Research. 16(10). 1568–1578. 6 indexed citations
11.
Chen, Yang, Hikaru Sugimoto, Keizo Kanasaki, et al.. (2018). Podoplanin+ tumor lymphatics are rate limiting for breast cancer metastasis. PLoS Biology. 16(12). e2005907–e2005907. 20 indexed citations
12.
Chen, Yang, Valerie S. LeBleu, Julienne L. Carstens, et al.. (2018). Dual reporter genetic mouse models of pancreatic cancer identify an epithelial‐to‐mesenchymal transition‐independent metastasis program. EMBO Molecular Medicine. 10(10). 59 indexed citations
13.
Zheng, Xiaofeng, Julienne L. Carstens, Jiha Kim, et al.. (2015). Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527(7579). 525–530. 1591 indexed citations breakdown →
14.
LeBleu, Valerie S., Gangadhar Taduri, Joyce T. O’Connell, et al.. (2013). Origin and function of myofibroblasts in kidney fibrosis. Nature Medicine. 19(8). 1047–1053. 1023 indexed citations breakdown →
15.
Duncan, Michael B., Changqing Yang, Harikrishna Tanjore, et al.. (2013). Type XVIII collagen is essential for survival during acute liver injury in mice. Disease Models & Mechanisms. 6(4). 942–51. 26 indexed citations
16.
LeBleu, Valerie S., Malin Sund, Hikaru Sugimoto, et al.. (2010). Identification of the NC1 Domain of α3 Chain as Critical for α3α4α5 Type IV Collagen Network Assembly. Journal of Biological Chemistry. 285(53). 41874–41885. 18 indexed citations
17.
Dandapani, Savita, Hikaru Sugimoto, Benjamin D. Matthews, et al.. (2006). α-Actinin-4 Is Required for Normal Podocyte Adhesion. Journal of Biological Chemistry. 282(1). 467–477. 104 indexed citations
18.
Sund, Malin, Yuki Hamano, Hikaru Sugimoto, et al.. (2005). Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proceedings of the National Academy of Sciences. 102(8). 2934–2939. 130 indexed citations
19.
Reiser, Jochen, Gero von Gersdorff, Martin Loos, et al.. (2004). Induction of B7-1 in podocytes is associated with nephrotic syndrome. Journal of Clinical Investigation. 113(10). 1390–1397. 442 indexed citations
20.
Hamano, Yuki, Michael Zeisberg, Hikaru Sugimoto, et al.. (2003). Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell. 3(6). 589–601. 428 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Zeisberg Breakdown of academic impact, for papers by Peter J. Nelson Breakdown of academic impact, for papers by David L. Lacey Breakdown of academic impact, for papers by Dontscho Kerjaschki Breakdown of academic impact, for papers by Elena Aïkawa Breakdown of academic impact, for papers by Benedetta Bussolati Breakdown of academic impact, for papers by Ying E. Zhang Breakdown of academic impact, for papers by Keith A. Hruska Breakdown of academic impact, for papers by Hans‐Peter Gerber Breakdown of academic impact, for papers by Lucia R. Languino
Rankless by CCL
2026